PASG Valuation

Passage Bio Inc

Add to Watchlist

Advanced Chart

6.950

-0.64(-8.432%)1D

Overview
Forecast
Valuation
Earnings

PASG Relative Valuation

PASG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PASG is overvalued; if below, it's undervalued.

Historical Valuation

Passage Bio Inc (PASG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.96. The fair price of Passage Bio Inc (PASG) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：6.95

Fair

-0.71

Trailing

Forward

0.00

EV/EBITDA

Passage Bio Inc. (PASG) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.21. The thresholds are as follows: Strongly Undervalued below -3.64, Undervalued between -3.64 and -1.93, Fairly Valued between 1.50 and -1.93, Overvalued between 1.50 and 3.21, and Strongly Overvalued above 3.21. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.19

EV/EBIT

Passage Bio Inc. (PASG) has a current EV/EBIT of 0.19. The 5-year average EV/EBIT is -0.26. The thresholds are as follows: Strongly Undervalued below -3.74, Undervalued between -3.74 and -2.00, Fairly Valued between 1.48 and -2.00, Overvalued between 1.48 and 3.23, and Strongly Overvalued above 3.23. The current Forward EV/EBIT of 0.19 falls within the Historic Trend Line -Fairly Valued range.

0.00

Passage Bio Inc. (PASG) has a current PS of 0.00. The 5-year average PS is 1.64. The thresholds are as follows: Strongly Undervalued below -10.36, Undervalued between -10.36 and -4.36, Fairly Valued between 7.64 and -4.36, Overvalued between 7.64 and 13.64, and Strongly Overvalued above 13.64. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Passage Bio Inc. (PASG) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.80. The thresholds are as follows: Strongly Undervalued below -6.84, Undervalued between -6.84 and -4.32, Fairly Valued between 0.72 and -4.32, Overvalued between 0.72 and 3.24, and Strongly Overvalued above 3.24. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Passage Bio Inc. (PASG) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.89. The thresholds are as follows: Strongly Undervalued below -6.90, Undervalued between -6.90 and -4.39, Fairly Valued between 0.62 and -4.39, Overvalued between 0.62 and 3.13, and Strongly Overvalued above 3.13. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Passage Bio Inc (PASG) has a current Price-to-Book (P/B) ratio of 0.58. Compared to its 3-year average P/B ratio of 0.44 , the current P/B ratio is approximately 29.90% higher. Relative to its 5-year average P/B ratio of 0.92, the current P/B ratio is about -37.11% higher. Passage Bio Inc (PASG) has a Forward Free Cash Flow (FCF) yield of approximately -152.44%. Compared to its 3-year average FCF yield of -169.96%, the current FCF yield is approximately -10.31% lower. Relative to its 5-year average FCF yield of -118.71% , the current FCF yield is about 28.41% lower.

0.58

P/B

Median3y

0.44

Median5y

0.92

-152.44

FCF Yield

Median3y

-169.96

Median5y

-118.71

Competitors Valuation Multiple

The average P/S ratio for PASG's competitors is 20.49, providing a benchmark for relative valuation. Passage Bio Inc Corp (PASG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CytoMed Therapeutics Ltd

SAB Biotherapeutics Inc

Performance Decomposition

Market capitalization of PASG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PASG in the past 1 year is driven by Unknown.